The Epigenomics of Cancer

Cell

Volumn 128, Issue 4, 2007, Pages 683-692

  Jones, Peter A ^a   Baylin, Stephen B ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; POLYPHENOL; PROCAINAMIDE;

CANCER; CANCER GROWTH; CANCER STEM CELL; CARCINOGENESIS; CHROMATIN ASSEMBLY AND DISASSEMBLY; CPG ISLAND; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE SILENCING; GENETIC REGULATION; GENOMICS; HUMAN; NUCLEOSOME; PRIORITY JOURNAL; REVIEW; X CHROMOSOME;

ANIMALS; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENE THERAPY; HUMANS; MUTATION; NEOPLASMS; STEM CELLS;

EID: 33847065486     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cell.2007.01.029     Document Type: Review

References (90)

1. Akiyama Y., Watkins N., Suzuki H., Jair K.W., van Engeland M., Esteller M., Sakai H., Ren C.Y., Yuasa Y., Herman J.G., and Baylin S.B. GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol. Cell. Biol. 23 (2003) 8429-8439
2. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., and Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 100 (2003) 3983-3988
3. Bakker J., Lin X., and Nelson W.G. Methyl-CpG binding domain protein 2 represses transcription from hypermethylated pi-class glutathione S-transferase gene promoters in hepatocellular carcinoma cells. J. Biol. Chem. 277 (2002) 22573-22580
4. Baylin S.B., and Ohm J.E. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?. Nat. Rev. Cancer 6 (2006) 107-116
5. Belinsky S.A., Nikula K.J., Palmisano W.A., Michels R., Saccomanno G., Gabrielson E., Baylin S.B., and Herman J.G. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl. Acad. Sci. USA 95 (1998) 11891-11896
6. Bernstein B.E., Mikkelsen T.S., Xie X., Kamal M., Huebert D.J., Cuff J., Fry B., Meissner A., Wernig M., Plath K., et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125 (2006) 315-326
7. Bernstein E., Duncan E.M., Masui O., Gil J., Heard E., and Allis C.D. Mouse polycomb proteins bind differentially to methylated histone H3 and RNA and are enriched in facultative heterochromatin. Mol. Cell. Biol. 26 (2006) 2560-2569
8. Bjerkvig R., Tysnes B.B., Aboody K.S., Najbauer J., and Terzis A.J. Opinion: the origin of the cancer stem cell: current controversies and new insights. Nat. Rev. Cancer 5 (2005) 899-904
9. Bolden J.E., Peart M.J., and Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5 (2006) 769-784
10. Boyer L.A., Plath K., Zeitlinger J., Brambrink T., Medeiros L.A., Lee T.I., Levine S.S., Wernig M., Tajonar A., Ray M.K., et al. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 441 (2006) 349-353
11. Bracken A.P., Dietrich N., Pasini D., Hansen K.H., and Helin K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev. 20 (2006) 1123-1136
12. Bracken A.P., Pasini D., Capra M., Prosperini E., Colli E., and Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 22 (2003) 5323-5335
13. Brueckner B., Boy R.G., Siedlecki P., Musch T., Kliem H.C., Zielenkiewicz P., Suhai S., Wiessler M., and Lyko F. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res. 65 (2005) 6305-6311
14. Cadieux B., Ching T.T., Vandenberg S.R., and Costello J.F. Genome-wide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate reductase allele status, and increased proliferation. Cancer Res. 66 (2006) 8469-8476
15. Cameron E.E., Bachman K.E., Myohanen S., Herman J.G., and Baylin S.B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21 (1999) 103-107
16. Chai J., Charboneau A.L., Betz B.L., and Weissman B.E. Loss of the hSNF5 gene concomitantly inactivates p21CIP/WAF1 and p16INK4a activity associated with replicative senescence in A204 rhabdoid tumor cells. Cancer Res. 65 (2005) 10192-10198
17. Chen W.Y., Wang D.H., Yen R.C., Luo J., Gu W., and Baylin S.B. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 123 (2005) 437-448
18. Cheng J.C., Yoo C.B., Weisenberger D.J., Chuang J., Wozniak C., Liang G., Marquez V.E., Greer S., Orntoft T.F., Thykjaer T., and Jones P.A. Preferential response of cancer cells to zebularine. Cancer Cell 6 (2004) 151-158
19. Chuang J.C., Yoo C.B., Kwan J.M., Li T.W., Liang G., Yang A.S., and Jones P.A. Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2′-deoxycytidine. Mol. Cancer Ther. 4 (2005) 1515-1520
20. Constantinides P.G., Jones P.A., and Gevers W. Functional striated muscle cells from non-myoblast precursors following 5-azacytidine treatment. Nature 267 (1977) 364-366
21. Cornacchia E., Golbus J., Maybaum J., Strahler J., Hanash S., and Richardson B. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J. Immunol. 140 (1988) 2197-2200
22. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860-867
23. Eckhardt F., Lewin J., Cortese R., Rakyan V.K., Attwood J., Burger M., Burton J., Cox T.V., Davies R., Down T.A., et al. DNA methylation profiling of human chromosomes 6, 20 and 22. Nat. Genet. 38 (2006) 1378-1385
24. Esteller M., Sparks A., Toyota M., Sanchez-Cespedes M., Capella G., Peinado M.A., Gonzalez S., Tarafa G., Sidransky D., Meltzer S.J., et al. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res. 60 (2000) 4366-4371
25. Esteller M., Fraga M.F., Guo M., Garcia-Foncillas J., Hedenfalk I., Godwin A.K., Trojan J., Vaurs-Barriere C., Bignon Y.J., Ramus S., et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum. Mol. Genet. 10 (2001) 3001-3007
26. Fang M.Z., Wang Y., Ai N., Hou Z., Sun Y., Lu H., Welsh W., and Yang C.S. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. 63 (2003) 7563-7570
27. Feinberg A.P., and Tycko B. The history of cancer epigenetics. Nat. Rev. Cancer 4 (2004) 143-153
28. Feinberg A.P., Ohlsson R., and Henikoff S. The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 7 (2006) 21-33
29. Foster S.A., Wong D.J., Barrett M.T., and Galloway D.A. Inactivation of p16 in human mammary epithelial cells by CpG island methylation. Mol. Cell. Biol. 18 (1998) 1793-1801
30. Fraga M.F., Ballestar E., Villar-Garea A., Boix-Chornet M., Espada J., Schotta G., Bonaldi T., Haydon C., Ropero S., Petrie K., et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 37 (2005) 391-400
31. Frigola J., Song J., Stirzaker C., Hinshelwood R.A., Peinado M.A., and Clark S.J. Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat. Genet. 38 (2006) 540-549
32. Futscher B.W., Oshiro M.M., Wozniak R.J., Holtan N., Hanigan C.L., Duan H., and Domann F.E. Role for DNA methylation in the control of cell type specific maspin expression. Nat. Genet. 31 (2002) 175-179
33. Gao X., Sedgwick T., Shi Y.B., and Evans T. Distinct functions are implicated for the GATA-4, -5, and -6 transcription factors in the regulation of intestine epithelial cell differentiation. Mol. Cell. Biol. 18 (1998) 2901-2911
34. Graff J.R., Herman J.G., Lapidus R.G., Chopra H., Xu R., Jarrard D.F., Isaacs W.B., Pitha P.M., Davidson N.E., and Baylin S.B. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 55 (1995) 5195-5199
35. Guarente L. Sir2 links chromatin silencing, metabolism, and aging. Genes Dev. 14 (2000) 1021-1026
36. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
37. Harikrishnan K.N., Chow M.Z., Baker E.K., Pal S., Bassal S., Brasacchio D., Wang L., Craig J.M., Jones P.L., Sif S., and El-Osta A. Brahma links the SWI/SNF chromatin-remodeling complex with MeCP2-dependent transcriptional silencing. Nat. Genet. 37 (2005) 254-264
38. Janzen V., Forkert R., Fleming H.E., Saito Y., Waring M.T., Dombkowski D.M., Cheng T., DePinho R.A., Sharpless N.E., and Scadden D.T. Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature 443 (2006) 421-426
39. Jenuwein T. The epigenetic magic of histone lysine methylation. FEBS J. 273 (2006) 3121-3135
40. Jones P.A., and Taylor S.M. Cellular differentiation, cytidine analogs and DNA methylation. Cell 20 (1980) 85-93
41. Jones P.A., and Laird P.W. Cancer epigenetics comes of age. Nat. Genet. 21 (1999) 163-167
42. Jones P.A., and Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3 (2002) 415-428
43. Jones P.L., Veenstra G.J., Wade P.A., Vermaak D., Kass S.U., Landsberger N., Strouboulis J., and Wolffe A.P. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet. 19 (1998) 187-191
44. Karpf A.R., Peterson P.W., Rawlins J.T., Dalley B.K., Yang Q., Albertsen H., and Jones D.A. Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells. Proc. Natl. Acad. Sci. USA 96 (1999) 14007-14012
45. Kimura A., Umehara T., and Horikoshi M. Chromosomal gradient of histone acetylation established by Sas2p and Sir2p functions as a shield against gene silencing. Nat. Genet. 32 (2002) 370-377
46. Kinzler K.W., and Vogelstein B. Lessons from hereditary colorectal cancer. Cell 87 (1996) 159-170
47. Kiyono T., Foster S.A., Koop J.I., McDougall J.K., Galloway D.A., and Klingelhutz A.J. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 396 (1998) 84-88
48. Knoepfler P.S., Zhang X.Y., Cheng P.F., Gafken P.R., McMahon S.B., and Eisenman R.N. Myc influences global chromatin structure. EMBO J. 25 (2006) 2723-2734
49. Krishnamurthy J., Ramsey M.R., Ligon K.L., Torrice C., Koh A., Bonner-Weir S., and Sharpless N.E. p16INK4a induces an age-dependent decline in islet regenerative potential. Nature 443 (2006) 453-457
50. Kuzmichev A., Margueron R., Vaquero A., Preissner T.S., Scher M., Kirmizis A., Ouyang X., Brockdorff N., Abate-Shen C., Farnham P., and Reinberg D. Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc. Natl. Acad. Sci. USA 102 (2005) 1859-1864
51. Laverriere A.C., MacNeill C., Mueller C., Poelmann R.E., Burch J.B., and Evans T. GATA-4/5/6, a subfamily of three transcription factors transcribed in developing heart and gut. J. Biol. Chem. 269 (1994) 23177-23184
52. Lee T.I., Jenner R.G., Boyer L.A., Guenther M.G., Levine S.S., Kumar R.M., Chevalier B., Johnstone S.E., Cole M.F., Isono K., et al. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 125 (2006) 301-313
53. Li H., Ilin S., Wang W., Duncan E.M., Wysocka J., Allis C.D., and Patel D.J. Molecular basis for site-specific read-out of histone H3K4me3 by the BPTF PHD finger of NURF. Nature 442 (2006) 91-95
54. Liang G., Gonzales F.A., Jones P.A., Orntoft T.F., and Thykjaer T. Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2′-deoxycytidine. Cancer Res. 62 (2002) 961-966
55. Lu H., Ouyang W., and Huang C. Inflammation, a key event in cancer development. Mol. Cancer Res. 4 (2006) 221-233
56. Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., and Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1 (2001) 194-202
57. McDermott K.M., Zhang J., Holst C.R., Kozakiewicz B.K., Singla V., and Tlsty T.D. p16(INK4a) prevents centrosome dysfunction and genomic instability in primary cells. PLoS Biol. 4 (2006) e51
58. McGarvey K.M., Fahrner J.A., Greene E., Martens J., Jenuwein T., and Baylin S.B. Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res. 66 (2006) 3541-3549
59. Minucci S., and Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6 (2006) 38-51
60. Molkentin J.D., Lin Q., Duncan S.A., and Olson E.N. Requirement of the transcription factor GATA4 for heart tube formation and ventral morphogenesis. Genes Dev. 11 (1997) 1061-1072
61. Molofsky A.V., Slutsky S.G., Joseph N.M., He S., Pardal R., Krishnamurthy J., Sharpless N.E., and Morrison S.J. Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing. Nature 443 (2006) 448-452
62. Nan X., Ng H.H., Johnson C.A., Laherty C.D., Turner B.M., Eisenman R.N., and Bird A. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393 (1998) 386-389
63. Nelson W.G., De Marzo A.M., DeWeese T.L., and Isaacs W.B. The role of inflammation in the pathogenesis of prostate cancer. J. Urol. 172 (2004) S6-S12
64. Orlando V. Polycomb, epigenomes, and control of cell identity. Cell 112 (2003) 599-606
65. Pirrotta V., and Gross D.S. Epigenetic silencing mechanisms in budding yeast and fruit fly: different paths, same destinations. Mol. Cell 18 (2005) 395-398
66. Pruitt K., Zinn R.L., Ohm J.E., McGarvey K.M., Kang S.H., Watkins D.N., Herman J.G., and Baylin S.B. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet. 2 (2006) e40
67. Reynolds P.A., Sigaroudinia M., Zardo G., Wilson M.B., Benton G.M., Miller C.J., Hong C., Fridlyand J., Costello J.F., and Tlsty T.D. Tumor suppressor p16INK4A regulates polycomb-mediated DNA hypermethylation in human mammary epithelial cells. J. Biol. Chem. 281 (2006) 24790-24802
68. Riggs A.D., and Jones P.A. 5-methylcytosine, gene regulation, and cancer. Adv. Cancer Res. 40 (1983) 1-30
69. Ringrose L., and Paro R. Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins. Annu. Rev. Genet. 38 (2004) 413-443
70. Roberts C.W., and Orkin S.H. The SWI/SNF complex-chromatin and cancer. Nat. Rev. Cancer 4 (2004) 133-142
71. Saito Y., Liang G., Egger G., Friedman J.M., Chuang J.C., Coetzee G.A., and Jones P.A. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9 (2006) 435-443
72. Santi D.V., Garrett C.E., and Barr P.J. On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs. Cell 33 (1983) 9-10
73. Schlesinger Y., Straussman R., Keshet I., Farkash S., Hecht M., Zimmerman J., Eden E., Yakhini Z., Ben-Shushan E., Reubinoff B.E., et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat. Genet. 39 (2007) 232-236
74. Seligson D.B., Horvath S., Shi T., Yu H., Tze S., Grunstein M., and Kurdistani S.K. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435 (2005) 1262-1266
75. Sharpless N.E., and DePinho R.A. Cancer: crime and punishment. Nature 436 (2005) 636-637
76. Suka N., Luo K., and Grunstein M. Sir2p and Sas2p opposingly regulate acetylation of yeast histone H4 lysine16 and spreading of heterochromatin. Nat. Genet. 32 (2002) 378-383
77. Suzuki H., Watkins D.N., Jair K.W., Schuebel K.E., Markowitz S.D., Chen W.D., Pretlow T.P., Yang B., Akiyama Y., Van Engeland M., et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat. Genet. 36 (2004) 417-422
78. Takai D., and Jones P.A. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc. Natl. Acad. Sci. USA 99 (2002) 3740-3745
79. Tamaru H., and Selker E.U. Synthesis of signals for de novo DNA methylation in Neurospora crassa. Mol. Cell. Biol. 23 (2003) 2379-2394
80. Toyota M., Ahuja N., Ohe-Toyota M., Herman J.G., Baylin S.B., and Issa J.P. CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. USA 96 (1999) 8681-8686
81. Valenta T., Lukas J., Doubravska L., Fafilek B., and Korinek V. HIC1 attenuates Wnt signaling by recruitment of TCF-4 and beta-catenin to the nuclear bodies. EMBO J. 25 (2006) 2326-2337
82. Valk-Lingbeek M.E., Bruggeman S.W., and van Lohuizen M. Stem cells and cancer; the polycomb connection. Cell 118 (2004) 409-418
83. Varambally S., Dhanasekaran S.M., Zhou M., Barrette T.R., Kumar-Sinha C., Sanda M.G., Ghosh D., Pienta K.J., Sewalt R.G., Otte A.P., et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419 (2002) 624-629
84. Vire E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C., Morey L., Van Eynde A., Bernard D., Vanderwinden J.M., et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439 (2006) 871-874
85. Weisenberger D.J., Siegmund K.D., Campan M., Young J., Long T.I., Faasse M.A., Kang G.H., Widschwendter M., Weener D., Buchanan D., et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 38 (2006) 787-793
86. Widschwendter M., Fiegl H., Egle D., Mueller-Holzner E., Spizzo G., Marth C., Weisenberger D.J., Campan M., Young J., Jacobs I., and Laird P.W. Epigenetic stem cell signature in cancer. Nat. Genet. 39 (2007) 157-158
87. Wysocka J., Swigut T., Xiao H., Milne T.A., Kwon S.Y., Landry J., Kauer M., Tackett A.J., Chait B.T., Badenhorst P., et al. A PHD finger of NURF couples histone H3 lysine 4 trimethylation with chromatin remodelling. Nature 442 (2006) 86-90
88. Yamashita K., Upadhyay S., Osada M., Hoque M.O., Xiao Y., Mori M., Sato F., Meltzer S.J., and Sidransky D. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2 (2002) 485-495
89. Yamashita K., Dai T., Dai Y., Yamamoto F., and Perucho M. Genetics supersedes epigenetics in colon cancer phenotype. Cancer Cell 4 (2003) 121-131
90. Zhang Y., Ng H.H., Erdjument-Bromage H., Tempst P., Bird A., and Reinberg D. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev. 13 (1999) 1924-1935